Nevro Corp (NYSE:NVRO), a medical device ... position that was initially anticipated based on clinical trial outcomes. The U.S. SCS market remains highly competitive, with larger companies ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Despite these initiatives, Nevro continues to face significant challenges in maintaining and growing its market share. The company's high-frequency SCS technology, while clinically proven, has not ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European ... as well as U.S. trial procedures, declined in the fourth quarter. However, NVRO is likely ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures ... cord stimulation (SCS) system. In addition to the U.S. market release, Nevro introduced the ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year ... pain management platform that powers the HFX iQ spinal cord ...